Immport Therapeutics Inc.

Immport Therapeutics Inc., doing business as Antigen Discovery Inc., develops protein microarray technology and diagnostic products for infectious disease research as a prime recipient of federal research grants and contracts, competing in full-and-open (non-set-aside) procurements from health and defense agencies. The Irvine, California–based biotechnology company holds no SBA set-aside certifications and operates as a for-profit corporate entity.

Immport's federal footprint centers on NIAID research grants and CDC product contracts supporting vaccine development and serology diagnostics. The National Institute of Allergy and Infectious Diseases accounts for 15 awards with $300 thousand in combined potential value, predominantly research grants under the Allergy and Infectious Diseases Research program (CFDA 93.855). The Centers for Disease Control and Prevention ranks second with 7 awards totaling $776 thousand in potential value, anchored by a $179 thousand purchase order for monkeypox microarray products and services awarded in August 2023. Recent prime work includes a $300 thousand firm fixed price contract from NIAID for development of a herpes simplex types 1 and 2 serology test (SBIR 133 phase, ultimate completion September 2025), a $300 thousand NIAID grant award in August 2026 for discovery of Group A Streptococcus vaccine antigens using pangenomic protein microarray screening (completion July 2028), and a $300 thousand NIAID grant in August 2025 for optimization of cryptosporidium vaccine candidates in collaboration with the University of Virginia (completion July 2027). Additional grant work spans pertussis serology potency testing, enteric virus immunology research in Bangladesh, and porcine brucellosis diagnostics awarded by NIAID and the Department of Agriculture's Institute of Food Production and Sustainability. The vendor also carries sub-award engagement as a service provider on a University of Southern California syphilis immunology grant (September 2025) and as a protein microarray service provider on a University of Virginia cryptosporidiosis field studies grant (September 2024).

Immport's customer concentration is heavily weighted toward DHHS agencies, with NIAID and CDC accounting for 80% of recent awards. The top five customer entities by count cover 80% of the award portfolio; the same top four by dollar value represent 90% of combined potential value. Activity has been modest at one to three awards annually over the past five years. The vendor operates predominantly as a prime (95% of awards) with minimal subcontracting footprint. SCI-reported federal services activity shows negligible scale, with 0.9 FTEs delivered as a named subcontractor in FY2025 — indicating that Immport's federal revenue derives primarily from research grants and product contracts rather than from billable service-hour delivery. Three awards face ultimate completion within the next twenty-four months, exposing modest recompete opportunity. Immport's core capability — high-throughput protein microarray fabrication, screening, and analysis for pathogen antigen discovery — is driven by federal research investment in infectious disease vaccine and diagnostic development, with demonstrated expertise in recombinant protein cloning, in vitro transcription and translation, and immunological data analysis across pathogens including monkeypox, SARS-CoV-2, cryptosporidium, streptococcus, pertussis, and brucella.